Bioretec Ltd | Press Release | 17 June 2026 at 16:00 EEST
Bioretec Ltd, a pioneer in absorbable orthopedic implants, has appointed Conan Cavanagh as Head of Research & Development and as a member of the management team as of 1 September 2026. Cavanagh will report directly to CEO Sarah van Hellenberg Hubar-Fisher.
Conan Cavanagh has over 25 years of experience in the development of medical devices, biomaterials, and product commercialization. He currently serves as Chief Operating Officer and Head of Research & Development at HidraMed Solutions. Previously, among other positions, he has served as Engineering Director at Smith & Nephew, where he was broadly responsible for the development and commercialization of orthopedic and sports medicine products.
Cavanagh has a bachelor's degree in biomedical engineering and also holds a master's degree in management. He has extensive experience across the full lifecycle of product development, from concept generation to commercialization. In addition, he has deep expertise in clinical studies, regulatory processes and intellectual property management.
In his new role at Bioretec, Cavanagh will be responsible for the company's research and development strategy, management of the product portfolio, and the execution of the product development program. He will have a central role in strengthening Bioretec's technological development, clinical evidence and regulatory readiness, as well as in supporting the company's long-term growth and international competitiveness.
"I am very pleased to be joining Bioretec's team at this important stage and to have the opportunity to advance the company's growth through innovation and new technology," says Conan Cavanagh.
"We are thrilled to welcome Conan Cavanagh to Bioretec. We look forward to his leadership and input as we continue on our mission to become the global market leader in absorbable orthopedic implants. Conan joins us at a pivotal and exciting stage in the company's development, and we are excited to see his significant contribution to executing our strategy, advancing our technology and supporting our international growth," says CEO Sarah van Hellenberg Hubar-Fisher.
Further enquiries
Sarah van Hellenberg Hubar-Fisher, CEO, +31 6 1544 8736
Certified adviser
Nordic Certified Adviser AB, +46 70 551 67 29
Information about Bioretec
Bioretec is a globally operating Finnish medical device pioneer at the forefront of transforming orthopedic care with fully biodegradable implant technologies. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries.
The company's latest innovation, the RemeOs™ product line, is based on a high-performance magnesium alloy and hybrid composite, introducing a new generation of strong absorbable materials for enhanced surgical outcomes. The RemeOs implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The first RemeOs product market authorization was received in the U.S. in March 2023, and in Europe, the CE mark approval was received in January 2025.
Bioretec's Activa product line features fully bioabsorbable orthopedic implants made from a proprietary, self-reinforced PLGA both CE marked and FDA cleared for a wide range of indications in adult and pediatric patients.
Bioretec is shaping the future of orthopedic treatment with a focus on healing through absorption, paving the way for more effective and patient-friendly solutions.
To learn more about Bioretec, visit www.bioretec.com